Endovascular Stenting

Slide 1 · Endovascular Stenting

Vascular injury, thrombosis and neointimal restenosis

Pathology-centered lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning goals

Explain why balloon angioplasty is usually coupled with stent placement.

Distinguish acute stent thrombosis from later neointimal restenosis.

Trace vascular injury to smooth-muscle migration, proliferation and matrix deposition.

Interpret the pathology of drug-eluting stents as a benefit–healing trade-off.

Slide 3 · Stenting addresses a mechanical lesion

Atherosclerotic plaque narrows an artery

Balloon expansion disrupts the plaque

Stent scaffolds the lumen

Wall injury can trigger new disease

Mechanical restoration of caliber does not eliminate the tissue response to intervention.

Slide 4 · Coronary stenoses are the principal example

The Robbins discussion emphasizes arterial stenoses, particularly coronary arteries.

Plaque enlargement progressively compromises the blood-flow lumen.

Endovascular treatment aims to enlarge the lumen without replacing the vessel.

The treated vessel remains biologically reactive after mechanical expansion.

Slide 5 · Normal arterial wall: Layers at risk

Intima: Endothelial lining with a thin matrix compartment.

Media: Circumferential smooth muscle and structural support.

Adventitia: Outer connective-tissue compartment.

Intervention affects the lumen-facing intima and underlying wall.

Schematic cross-section

Slide 6 · The endothelium is a functional surface

Intact endothelial cells help regulate blood flow and thrombosis.

Normal endothelium balances antithrombotic and prothrombotic properties.

Loss or dysfunction of the lining shifts the wall toward thrombosis.

This explains the importance of endothelial injury after stenting.

Slide 7 · Smooth muscle has two relevant phenotypes

Contractile medial SMC

Predominantly quiescent

Regulates arterial tone

Provides mechanical support

Proliferative neointimal SMC

Responds to injury signals

Migrates and expands in the intima

Synthesizes extracellular matrix

Slide 8 · Atherosclerotic plaque narrows the lumen

Atheromatous material occupies the intimal compartment.

Lesions are commonly eccentric rather than concentric.

Advanced plaque growth eventually constricts the residual lumen.

Restricted flow provides the rationale for revascularization.

Eccentric plaque — schematic

Slide 9 · Stenosis links anatomy to ischemia

A narrowed arterial lumen increases resistance to flow.

At severe narrowing, perfusion may no longer meet tissue demand.

Anatomical re-expansion can improve symptoms by restoring flow.

The intervention is directed at stenosis, not the systemic cause of atherosclerosis.

Slide 10 · Balloon angioplasty: Sequence

Catheter reaches narrowed segment

Balloon expands briefly under pressure

Plaque is fractured / compressed

A larger lumen remains

Balloon expansion restores lumen caliber by exerting force on the plaque.

Slide 11 · Balloon angioplasty disrupts obstructing plaque

Balloon

Transient balloon inflation applies radial force to the lesion.

The force can rupture or split the obstructive plaque.

Luminal enlargement is immediate but may be mechanically unstable.

Local injury initiates the vascular repair response.

Balloon expansion — schematic

Slide 12 · Clinical improvement does not guarantee patency

Angioplasty can initially alleviate symptoms of stenosis.

Rapid reclosure remains an important limitation of balloon-only treatment.

The problem may be mechanical, vasomotor or thrombotic.

Stent deployment specifically addresses several mechanical causes.

Slide 13 · Three routes to abrupt reclosure

Dissection compresses the lumen

Vessel wall spasm narrows caliber

Thrombosis blocks the lumen

Abrupt reclosure has three distinct mechanistic explanations.

Slide 14 · Angioplasty-related dissection

Plaque and wall disruption may produce an intimal flap.

A mobile flap can project into the lumen.

Resulting compression may produce abrupt closure.

Stent struts can hold the flap against the wall.

Flap — schematic

Slide 15 · Vasospasm is a second closure mechanism

Contraction of mural smooth muscle reduces vessel caliber.

Angioplasty may trigger spasm in the treated segment.

A narrowed lumen can reappear even without neointimal growth.

An expanded metallic scaffold mechanically restricts recoil or spasm.

Slide 16 · Thrombosis is a distinct acute hazard

Balloon-induced injury exposes a thrombogenic vascular interface.

An intraluminal clot can obstruct blood flow rapidly.

This is different from gradual tissue proliferation.

Deployment of a stent does not itself abolish thrombotic risk.

Slide 17 · Mechanical versus thrombotic reclosure

Structural / vasomotor

Dissection: Flap impinges on lumen

Spasm: Wall constricts

Stent can stabilize the affected region

Thrombotic

Platelet-rich thrombus may form after injury

Occlusion can occur abruptly

Requires antithrombotic protection

Slide 18 · Coronary stents are expandable metal meshes

A stent is a tubular metallic lattice deployed within the treated artery.

Its architecture supplies radial support to the vessel wall.

The device becomes part of the blood-contacting environment.

It changes mechanics immediately and cellular responses afterward.

Slide 19 · Scaffolding produces a more regular lumen

Struts oppose the vessel wall after expansion.

The stent holds a larger and more regular lumen.

Local scaffolding reduces inward motion of wall flaps.

The wall is still injured and therefore prone to repair responses.

Stent struts — schematic

Slide 20 · What a stent fixes mechanically

Inadequate post-balloon lumen

Dissection flaps

Constriction from vessel spasm

Radial scaffolding counteracts inward movement of the arterial wall.

Slide 21 · The stent changes vessel-wall geometry

Expansion enlarges the passage through the diseased segment.

Scaffolding apposes intimal flaps to the arterial wall.

The treated lumen becomes less susceptible to spasm-driven collapse.

Long-term patency still depends on biological healing.

Slide 22 · Before and after stent placement

Before

Plaque restricts the flow channel

Disrupted intima may protrude

Spasm may narrow the vessel

After

Mesh supports a wider lumen

Intimal flaps are constrained

Endothelial injury and thrombotic risk remain

Slide 23 · The source describes widespread combined use

That more than 95% of coronary endovascular procedures combine angioplasty and stenting.

The stated rationale is prevention of abrupt, mechanically driven reclosure.

This is a source-specific utilization statement, not a freshly verified current registry statistic.

Slide 24 · A successful device can still injure tissue

Balloon inflation and stent placement

Disruption of endothelial integrity

Thrombosis or reparative hyperplasia

Possible renewed lumen loss

Acute thrombosis and delayed hyperplasia are different consequences of injury.

Slide 25 · Stent implantation creates a thrombogenic interface

An intact endothelial barrier is disrupted during intervention.

Exposed damaged surfaces favor platelet adhesion and clot formation.

The metallic framework does not replace antithrombotic endothelial function.

Acute thrombosis can therefore follow technically successful stenting.

Slide 26 · Acute post-stenting thrombus

The stent maintains a mechanical lumen but cannot guarantee flow.

Endothelial injury makes occlusive thrombosis possible.

Thrombus occupies the blood-flow channel.

This is an early complication rather than a fibromuscular repair lesion.

Thrombus — schematic

Slide 27 · Early thrombotic occlusion: Causal chain

Endothelial denudation

Platelet activation / accumulation

Intraluminal thrombus

Abrupt flow obstruction

An acute thrombus can obstruct the entire treated lumen.

Slide 28 · Why antithrombotic treatment matters

Immediate post-stenting thrombotic risk.

Antiplatelet agents are described as the principal preventive therapy.

The objective is to avert acute, potentially catastrophic stent occlusion.

Drug choice and duration require contemporary clinical guidance outside this source-based lecture.

Slide 29 · Thrombosis and neointimal restenosis differ

Thrombotic occlusion

Clot forms within the lumen

Associated with the early injury period

Clinical problem: Sudden loss of patency

Neointimal restenosis

Smooth muscle + matrix expand the intima

Develops through tissue-repair processes

Clinical problem: Progressive lumen encroachment

Slide 30 · Injury triggers a stereotyped repair program

Vascular trauma elicits the same general healing response seen after other vessel insults.

Smooth muscle cells accumulate in the injured intima.

Extracellular matrix production expands the new tissue layer.

The resulting repair tissue can narrow a lumen that was just restored.

Slide 31 · Neointimal hyperplasia: Core sequence

Wall / endothelial injury

SMC recruitment to intima

SMC proliferation

ECM synthesis and intimal thickening

The apparent repair response can paradoxically re-create stenosis.

Slide 32 · The cellular origin of the neointima

Smooth muscle cells can enter the intima from the vascular media.

Circulating smooth-muscle precursors can also contribute.

These cells expand and produce extracellular matrix.

Their repair-like behavior resembles fibroblasts in a healing wound.

Slide 33 · Contractile-to-synthetic phenotype shift

Before injury

Medial SMCs mainly contractile

Relatively nonproliferative

Regulate tone and vessel mechanics

After injury

Neointimal SMCs more proliferative

Greater matrix biosynthesis

Reduced contractile emphasis

Slide 34 · Signals that drive smooth-muscle responses

Platelets, endothelial cells and macrophages release growth factors or cytokines.

Thrombin and activated complement also stimulate the repair phenotype.

These signals favor SMC migration, proliferation and matrix production.

The response can diminish after endothelial recovery.

Slide 35 · Smooth-muscle migration changes lesion location

SMCs reside mainly in the media

Signals recruit SMCs toward intima

Intimal SMC population increases

New tissue lies between blood and vessel wall

SMC migration places proliferative cells at the lumen-facing surface.

Slide 36 · Proliferation amplifies the response

A post-injury SMC phenotype can enter a proliferative state.

Expanding intimal cell numbers increase lesion volume.

This is a tissue-growth process, not thrombus deposition.

Antiproliferative stent drugs target this component of restenosis.

Slide 37 · Matrix accumulation is equally important

Activated SMCs synthesize collagen, elastin and proteoglycans.

Matrix is a structural component of the new intimal tissue.

Combined SMC accumulation and matrix deposition thicken the intima.

The pathologic consequence depends on the remaining lumen.

Slide 38 · Neointima is composed of cells and matrix

Recruitment of SMCs

Expansion of SMC population

Deposition of ECM

Fibromuscular intimal thickening

Neointimal expansion progressively reduces the open lumen.

Slide 39 · Restenosis: Tissue grows inside the stent

Stent struts remain embedded near the expanded wall.

A new cell- and matrix-rich intima develops over the struts.

Neointimal tissue reduces the residual open lumen.

The device may remain mechanically expanded despite tissue obstruction.

Late neointima — schematic

Slide 40 · Why the healed vessel may narrow again

Initial lumen gain is mechanical; Later lumen loss is biologic.

SMC migration and proliferation increase cellular content.

Extracellular matrix adds noncellular tissue volume.

Concentric intimal growth may produce clinically relevant obstruction.

Slide 41 · The macroscopic pattern of restenosis

The original atherosclerotic plaque persists after intervention.

Robbins Figure 11.33 describes residual yellow plaque material.

A newer tan-white concentric intimal lesion lies internal to the old plaque.

This layered pattern separates underlying disease from postprocedure repair.

Slide 42 · The microscopic pattern of restenosis

A thickened neointima overlies and separates metallic stent wires.

Neointimal expansion intrudes into the luminal space.

The Robbins example uses a Movat-stained tissue section.

The caption describes matrix staining as gray-green.

Slide 43 · Old plaque and new intima are not equivalent

Atherosclerotic substrate

Pre-existing intimal plaque

Lipid-rich atheromatous material may remain

Initiates the need for intervention

Post-stent lesion

Repair-associated fibromuscular neointima

SMCs + ECM cover stent struts

Can create restenosis without plaque reaccumulation

Slide 44 · Clinical time course of in-stent restenosis

Neointimal proliferation is a delayed consequence of vascular injury.

Clinically important re-narrowing within 6–12 months.

The cited estimate is up to one-third of patients after stenting.

This is a textbook-described historical estimate, not a device-specific current rate.

Slide 45 · Early and delayed hazards can be distinguished

Immediate / early

Stent-associated thrombosis

Mechanism: Endothelial damage and clot

Clinical behavior: Abrupt occlusion

Months later

Proliferative in-stent restenosis

Mechanism: SMCs + ECM

Clinical behavior: Progressive loss of lumen

Slide 46 · Drug-eluting stents target the cellular response

A drug-eluting stent releases antiproliferative drug into adjacent vessel tissue.

The intended effect is suppression of SMC activation and proliferation.

Reduced intimal hyperplasia helps preserve the luminal area.

Drug delivery changes healing biology; It does not remove the original plaque.

Slide 47 · Drug-eluting stent: Mechanism

Drug leaves stent surface

Adjacent wall receives antiproliferative agent

SMC response is suppressed

Less neointimal luminal encroachment

Local drug delivery interrupts the cellular growth response.

Slide 48 · Sirolimus and paclitaxel are source examples

Sirolimus as an antiproliferative stent drug.

Paclitaxel is also cited as an example.

Both are introduced here for their suppression of vascular SMC responses.

No drug dose, platform comparison or release kinetics by device is specified.

Slide 49 · Drug exposure is shorter than the clinical effect

Drug elution over days to weeks.

The intended effect on neointimal growth extends beyond release itself.

Restenosis reduction is assessed at a much later time point.

Short elution does not imply rapid endothelial recovery.

Slide 50 · The time scales are different

Procedure

Balloon inflation and stent deployment

Early phase

Thrombosis risk from endothelial injury

Days–weeks

Antiproliferative drug release

Months

Neointimal growth and potential restenosis

Late outcomes cannot be inferred from device expansion alone.

Slide 51 · The source reports reduced restenosis at one year

Drug-eluting stents reduce one-year restenosis by 50%–80%.

The passage does not specify which trials, comparators or stent models define the range.

Treat this as a textbook estimate, not a universal absolute-risk reduction.

Do not interpret it as an individual patient’s predicted response.

Slide 52 · Biological trade-off of antiproliferative therapy

Inhibit SMC expansion

Less neointimal restenosis

Endothelial repair slows

Thrombosis prevention remains critical

Reduced neointimal proliferation may coexist with slower surface healing.

Slide 53 · Reendothelialization closes the injury cycle

The endothelium can regenerate over previously denuded surfaces.

Adjacent endothelial cells and circulating precursors may participate in repair.

Normalization of the lining helps restrain excessive SMC responses.

Antiproliferative stent therapy can prolong this restorative process.

Slide 54 · Delayed healing affects antithrombotic needs

Drug-eluting stents reduce proliferative restenosis but slow endothelial recovery.

Robbins therefore describes extended antithrombotic treatment after deployment.

The same section chiefly identifies platelet antagonists as protection against thrombosis.

Specific contemporary regimens cannot be determined from this excerpt.

Slide 55 · Conventional and drug-eluting devices

Metallic scaffold (without drug)

Expands and regularizes the lumen

Stabilizes flaps, limits spasm

Still permits neointimal growth

Drug-eluting scaffold

Same mechanical scaffolding function

Local antiproliferative action

Reduced neointimal growth; Slower endothelial recovery

Slide 56 · Stent benefits and risks are linked

Early mechanical benefit

Larger, more uniform residual lumen

Less flap-related compression

Protection against mechanically mediated reclosure

Ongoing biologic liabilities

Immediate risk of thrombotic occlusion

Late fibromuscular intimal thickening

Delayed healing after antiproliferative stents

Slide 57 · Recognize three mechanisms of lumen loss

Dissection

Wall flap compresses the expanded lumen

Thrombosis

Blood clot acutely obstructs the lumen

Neointimal growth

SMCs and ECM create new intimal tissue

Slide 58 · Teaching case: Abrupt postprocedure closure

A stenotic coronary artery is dilated and a metallic mesh stent is deployed. Shortly afterward, flow suddenly falls.

Interpret the mechanism

Which early complication must be considered?

Why does mechanically successful expansion not prevent it?

Slide 59 · Case resolution: Acute stent thrombosis

Endothelial disruption creates a thrombotic substrate.

A clot can form within the newly treated segment despite scaffolding.

This differs from tissue-rich restenosis, which takes time to develop.

Platelet antagonism as preventive therapy.

Slide 60 · Teaching case: Re-narrowing months later

A coronary stent remains in position, but the treated segment narrows again several months after implantation.

Interpret the mechanism

What type of lesion is most characteristic?

Which cell and extracellular component create it?

Slide 61 · Case resolution: Neointimal restenosis

Smooth muscle cells accumulate and proliferate within the intima.

The cells deposit extracellular matrix around and over the stent struts.

The expanding neointima progressively diminishes the lumen.

A retained stent does not exclude a new biological stenosis.

Slide 62 · Teaching case: An antiproliferative trade-off

A stent is coated to release a drug that reduces smooth-muscle proliferation after vessel injury.

Interpret the mechanism

Which delayed complication is the coating designed to limit?

Which restorative process may also be prolonged?

Slide 63 · Case resolution: Control versus healing

Drug delivery suppresses the proliferative neointimal response.

This lowers the probability of re-narrowing account.

Endothelial restoration may also proceed more slowly.

The trade-off motivates continued attention to thrombotic protection.

Slide 64 · Stenting and grafting share a repair response

Stent-injured native artery

Balloon and strut trauma damage the wall

SMCs and matrix enlarge the neointima

Restenosis occurs within the supported segment

Vascular graft / bypass

Abnormal mechanical forces can injure vessels

SMCs and matrix thicken the intima

Stenosis may arise at graft interfaces

Slide 65 · Integrated pathology: Intervention to outcome

Luminal stenosis

Balloon + stent: Immediate lumen gain

Early hazard: Thrombosis

Late hazard: SMC/ECM restenosis

The clinical result depends on mechanical success and vascular healing.

Slide 66 · Five findings worth retaining

Stents provide a more regular, supported lumen after angioplasty.

Early failure may result from acute thrombosis despite scaffolding.

Late failure often reflects SMC-rich, matrix-rich neointimal proliferation.

Drug elution suppresses hyperplasia but can delay reendothelialization.

Device mechanics and vessel biology must both be considered.

Slide 67 · Self-assessment: Mechanistic checkpoints

Why can angioplasty alone be followed by abrupt lumen closure?

Which stent feature stabilizes intimal flaps?

What distinguishes neointima from a fresh thrombus?

How does drug elution modify both restenosis and healing?

Slide 68 · Selected textbook source

Robbins, Cotran & Kumar: Pathologic Basis of Disease

11th edition (2026) · Chapter 11: Blood Vessels

Arterial wall and intimal response: pp. 442–445

Atherosclerosis / stenosis: pp. 454–457

Pathology of intervention and stenting: pp. 477–478